Overview

Pilot of Letrozole for Uterine Myomas

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Letrozole